ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicNew Challenges in Cancer Immunotherapy: Mechanisms, Translational Approaches, and Pan-Tumor StrategiesView all 6 articles
Integrative multi-omics analysis identifies a PTM-related immune signature and IRF9 as a driver in ccRCC
Provisionally accepted
- 1Urology, Xuzhou Medical University, Xuzhou, China
- 2Emergency Center, Xuzhou Medical University, Xuzhou, China
- 3General Surgery,, Xuzhou Medical University, Xuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Clear cell renal cell carcinoma (ccRCC) exhibits marked heterogeneity and variable benefit from immune checkpoint inhibitors (ICIs). Post-translational modifications (PTMs) regulate immune signaling and tumor behavior, yet PTM-informed biomarkers for ccRCC remain underexplored. Methods: We intersected immune-related genes, PTM-related genes, and differentially expressed genes in TCGA-KIRC to derive candidates and built a prognostic model across TCGA and E-MTAB-1980 using multiple algorithms, selecting a random survival forest-based post-translational modification-related signature (PTMRS) with the best performance. Prognostic value and independence were evaluated by time-dependent ROC, Kaplan-Meier, and multivariate Cox analyses. Tumor immune context was profiled by immune infiltration scores, immune checkpoints, and TIDE to infer dysfunction/exclusion and ICI response. Genomic features (driver mutations, pathway alterations, tumor mutational burden) and an external ICI cohort (IMvigor210) were analyzed. Single-cell RNA-seq with CellChat, trajectory, and UCell assessed cell-cell communication and PTMRS distribution across immune subsets. Experimental validation included IHC and qPCR of IRF9, loss-and gain-of-function assays (Transwell, wound healing, CCK-8, colony, EdU), and molecular dynamics to explore IRF9 compound binding. Results: We established a five-gene PTMRS that robustly stratified prognosis in training, testing, and external cohorts and remained an independent predictor. High-PTMRS tumors displayed immunosuppressive features-greater infiltration of Tregs/MDSCs/macrophages, higher immunosuppressive checkpoints, and elevated TIDE with lower predicted ICI responsiveness. High PTMRS associated with alterations in oncogenic pathways and higher TMB. In IMvigor210, high PTMRS linked to inferior outcomes and non-response. Single-cell analyses showed PTMRS enrichment in Tregs and exhausted CD8+ T cells and dense immune communication networks. Among PTMRS genes, IRF9 was upregulated in ccRCC tissues and cell lines. Knockdown of IRF9 curtailed invasion, migration, and proliferation, whereas overexpression enhanced these phenotypes. Conclusion: PTMRS is a PTM-informed immune signature that reflects an immunosuppressive tumor microenvironment, improves prognostic stratification, and indicates ICI benefit in ccRCC. Experimental data pinpoint IRF9 as a functional driver and potential therapeutic target within this PTM-immunity axis.
Keywords: ccRCC, Post-translational modifications (PTMs), Tumor Microenvironment, Immunotherapy, single-cell RNA sequencing, IRF9
Received: 17 Sep 2025; Accepted: 14 Nov 2025.
Copyright: © 2025 Li, Li, Hu, Jiang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Junqi Wang, wjq68@sina.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.